Minimal residual disease analysis in myeloma - when, why and where.
Ontology highlight
ABSTRACT: The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the therapeutic decision making. A better definition of MRD will aid in tailoring MM therapy further to address the clonal heterogeneity and genomic instability and overcome patient's ineffective immune surveillance. MRD analysis can define the logical endpoint for maintenance therapy, in addition also aids in providing a better clinical end point for studies comparing novel agents in myeloma. MRD is a surrogate for the survival in MM. Guidelines for global incorporation of MRD in myeloma are fraught with lack of standardization, universal availability and abridged physicians' understanding of MRD modalities. We aimed at addressing some of the frequently
SUBMITTER: Yanamandra U
PROVIDER: S-EPMC6208356 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA